Progression of classic Kaposi's sarcoma with rituximab
- 31 July 2005
- journal article
- case report
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 53 (1), 155-157
- https://doi.org/10.1016/j.jaad.2004.12.048
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a north american seriesJournal of the American Academy of Dermatology, 2003
- Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 casesJournal of the American Academy of Dermatology, 2003
- Neutropenia in Patients Treated with RituximabNew England Journal of Medicine, 2003
- Kaposi's sarcoma and other manifestations of human herpesvirus 8Journal of the American Academy of Dermatology, 2002
- Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorderJournal of the American Academy of Dermatology, 2002
- Kaposi's SarcomaNew England Journal of Medicine, 2000
- Intralesional Therapy With Anti-CD20 Monoclonal Antibody Rituximab in Primary Cutaneous B-Cell LymphomaArchives of Dermatology, 2000